BACE1

BACE1

B-site amyloid precursor protein (APP) cleaving enzyme. An aspartic-acid protease encoded by BACE1 on chromosome 11q23.2.-q23.3, which is linked to the pathogenesis of Alzheimer's disease and the formation of myelin sheaths in peripheral nerve cells. BACE1 is a transmembrane aspartic protease (beta-secretase) found in the Golgi apparatus, trans-Golgi network, secretory vesicles, and endosomes. It cleaves amyloid precursor protein (APP) in the brain into amyloid beta peptide, a major component of the amyloid plaques of Alzheimer's disease (AD), the deposition of which is the central pathology in AD, for which BACE1 is potential therapeutic target.
Mentioned in ?
References in periodicals archive ?
The key was blocking a chemical called BACE1, which has been at the heart of dementia research for years.
The Alzheimer's [sz]-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques.
The aim will be to determine whether the BACE1 inhibitor CNP520 can prevent or delay the onset of Alzheimer's disease (AD) symptoms in a high-risk population.
M2 EQUITYBITES-November 3, 2017-Amgen, Novartis & the Banner Alzheimer's Institute (BAI) partnership to determine whether the BACE1 inhibitor CNP520 can prevent or delay the onset of Alzheimer's disease symptoms
New drugs based on BACE1 (beta-site amyloid precursor protein-cleaving enzyme 1) and gammasecretase have also not shown success.
10) BACE1 inhibitors (AZD3292, E2609), whose suppression induces neurite growth inhibition in experiments, is ongoing in Phase III clinical trial so far without inducing large side effects.
Regarding APP, BACE1 and PS1 protein expression and global DNA methylation pattern, no difference was observed throughout development in female or male offspring.
Verubecestat works differently to other drugs currently being tested for Alzheimer's, as the first BACE1 inhibitor to reach the final stages of testing in people.
Extensive genetic and pharmacological studies in animals and humans have shown that BACE1 inhibition has the potential to slow or halt the progression of AD with a sufficient therapeutic window for the requisite long term dosing.
Ginsenoside Rg1 attenuates beta-amyloid generation via suppressing PPARgamma-regulated BACE1 activity in N2a-APP695 cells.
In vitro, the allele blocked the effect of BACE1, reducing the production of Abeta42 by up to 50%.